Prophylactic and therapeutic efficacy of avian antibodies against influenza virus H5N1 and H1N1 in mice

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Nguyen, Huan H ^a,f   Tumpey, Terrence M ^b   Park, Hae Jung ^a   Byun, Young Ho ^c   Tran, Linh D ^d   Nguyen, Van D ^d   Kilgore, Paul E ^a   Czerkinsky, Cecil ^a   Katz, Jacqueline M ^b   Seong, Baik Lin ^c   Song, Jae Min ^c   Kim, Young Bong ^d   Do, Hoa T ^e   Nguyen, Tung ^e   Nguyen, Cam V ^e  

^a International Vaccine Institute   (South Korea)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c Yonsei University   (South Korea)

^d Konkuk University   (South Korea)

^e National Centre for Veterinary Diagnostics   (Viet Nam)

^f University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN Y; IMMUNOGLOBULIN; INFLUENZA VACCINE; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CROSS PROTECTION; DRUG EFFICACY; DRUG SAFETY; EGG YOLK; FEMALE; HEN; IMMUNIZATION; INFECTION CONTROL; INFLUENZA A (H1N1); INFLUENZA A (H5N1); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PANDEMIC; VIET NAM; VIRUS INACTIVATION; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; BIOSYNTHESIS; BIRD; CHICKEN; EGG; IMMUNOLOGY; POULTRY; VIROLOGY;

AVES; AVIAN INFLUENZA VIRUS; MUS; ORTHOMYXOVIRIDAE;

ANIMALS; ANTIBODIES, VIRAL; BIRDS; CHICKENS; EGGS; IMMUNIZATION; IMMUNOGLOBULINS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE; PANDEMICS; POULTRY; VIETNAM;

EID: 77956302071     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010152     Document Type: Article

References (44)

1. Ehrlich HJ, Muller M, Oh HML, Tambyah PA, Joukhadar C, et al. (2008) A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell Culture. N Engl J Med 358: 2573-2584.
2. Keller MA, Stiehm ER (2000) Passive Immunity in Prevention and Treatment of Infectious Diseases. Clin Microbiol Rev 13: 602-614.
3. Simmons CP, Bernasconi NL, Suguitan AL, Mills K, Ward JM, et al. (2007) Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 4: e178.
4. Lim AP, Chan CE, Wong SK, Chan AH, Ooi EE, et al. (2008) Neutralizing human monoclonal antibody against H5N1 influenza HA selected from a Fabphage display library. Virol J 5: 130.
5. Hanson BJ, Boon AC, Lim AP, Webb A, Ooi EE, et al. (2006) Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir Res 7: 126.
6. Sun L, Lu X, Li C, Wang M, Liu Q, et al. (2009) Generation, characterization and epitope mapping of two neutralizing and protective human recombinant antibodies against influenza A H5N1 viruses. PLoS One 4: e5476.
7. Cooper HM, Paterson Y (2009) Production of polyclonal antisera. Curr Protoc Neurosci Chapter 5: Unit 5 5.
8. Warr GW, Magor KE, Higgins DA (1995) IgY: clues to the origins of modern antibodies. Immunol Today 16: 392-398.
9. Carlander D, Stalberg J, Larsson A (1999) Chicken antibodies: a clinical chemistry perspective. Ups J Med Sci 104: 179-189.
10. Larsson A, Carlander D (2003) Oral immunotherapy with yolk antibodies to prevent infections in humans and animals. Ups J Med Sci 108: 129-140.
11. Nilsson E, Larsson A, Olesen HV, Wejaker PE, Kollberg H (2008) Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients. Pediatr Pulmonol 43: 892-899.
12. Peyre M, Fusheng G, Desvaux S, Roger F (2009) Avian influenza vaccines: a practical review in relation to their application in the field with a focus on the Asian experience. Epidemiol Infect 137: 1-21.
13. Anonymous. Vaccination: A tool for the Control of Avian Influenza. In: www.oie.int/verone, editor; 2007 March 20-22; Verona, Italy.
14. Nguyen HH, van Ginkel FW, Vu HL, McGhee JR, Mestecky J (2001) Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes. J Infect Dis 183: 368-376.
15. Richmond JY, McKinney RW (2007) Laboratory biosafety level criteria. Richmond JY, McKinney RW, eds. Atlanta, GA: Center for Disease Control and Prevention.
16. Akita EM, Nakai S (1992) Immunoglobulins from egg yolk: isolation and purification. J Food Sci 57: 629-634.
17. Akita EM, Nakai S (1993) Comparison of four purification methods for the production of immunoglobulins from eggs laid by hens immunized with an enterotoxigenic E. coli strain. J Immunol Methods 160: 207-214.
18. Nilsson E, Hanrieder J, Bergquist J, Larsson A (2008) Proteomic characterization of IgY preparations purified with a water dilution method. J Agric Food Chem 56: 11638-11642.
19. Maines TR, Lu XH, Erb SM, Edwards L, Guarner J, et al. (2005) Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol 79: 11788-11800.
20. Reed LJ, Muench HA (1938) A simple method of estimating fifty per cent endpoints. Am J Hyg 27: 493-497.
21. Tumpey TM, Basler CF, Aguilar PV, Zeng H, Solorzano A, et al. (2005) Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 310: 77-80.
22. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, et al. (1999) Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 37: 937-943.
23. Szretter KJ, Gangappa S, Belser JA, Zeng H, Chen H, et al. (2009) Early control of H5N1 influenza virus replication by the type I interferon response in mice. J Virol 83: 5825-5834.
24. Russell MW, Mestecky J, Julian BA, Galla JH (1986) IgA-associated renal diseases: antibodies to environmental antigens in sera and deposition of immunoglobulins and antigens in glomeruli. J Clin Immunol 6: 74-86.
25. Larsson A, Karlsson-Parra A, Sjoquist J (1991) Use of chicken antibodies in enzyme immunoassays to avoid interference by rheumatoid factors. Clin Chem 37: 411-414.
26. Walsh WE, Jr., Anderson BE, Ivancic D, Zhang Z, Piccini JP, et al. (2000) Distribution of, and immune response to, chicken anti-alpha Gal immunoglobulin Y antibodies in wild-type and alpha Gal knockout mice. Immunology 101: 467-473.
27. Carlander D, Kollberg H, Wejaker PE, Larsson A (2000) Peroral immunotherapy with yolk antibodies for the prevention and treatment of enteric infections. Immunol Res 21: 1-6.
28. Hatta H, Tsuda K, Ozeki M, Kim M, Yamamoto T, et al. (1997) Passive immunization against dental plaque formation in humans: effect of a mouth rinse containing egg yolk antibodies (IgY) specific to Streptococcus mutans. Caries Res 31: 268-274.
29. Suzuki H, Nomura S, Masaoka T, Goshima H, Kamata N, et al. (2004) Effect of dietary anti-Helicobacter pylori-urease immunoglobulin Y on Helicobacter pylori infection. Aliment Pharmacol Ther 20 Suppl 1: 185-192.
30. Horie K, Horie N, Abdou AM, Yang JO, Yun SS, et al. (2004) Suppressive effect of functional drinking yogurt containing specific egg yolk immunoglobulin on Helicobacter pylori in humans. J Dairy Sci 87: 4073-4079.
31. Kollberg H, Carlander D, Olesen H, Wejaker PE, Johannesson M, et al. (2003) Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study. Pediatr Pulmonol 35: 433-440.
32. Kong LK, Zhou BP (2006) Successful treatment of avian influenza with convalescent plasma. Hong Kong Med J 12: 489.
33. Tominack RL, Hayden FG (1987) Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections. Infect Dis Clin North Am 1: 459-478.
34. Gubareva LV, Kaiser L, Hayden FG (2000) Influenza virus neuraminidase inhibitors. Lancet 355: 827-835.
35. Anonymous (2005) Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis 11: 1515-1521.
36. Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, et al. (2005) Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366: 1175-1181.
37. Cheung CL, Rayner JM, Smith GJ, Wang P, Naipospos TS, et al. (2006) Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis 193: 1626-1629.
38. Deyde VM, Xu X, Bright RA, Shaw M, Smith CB, et al. (2007) Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 196: 249-257.
39. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, et al. (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353: 2667-2672.
40. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, et al. (2005) Avian flu: isolation of drug-resistant H5N1 virus. Nature 437: 1108.
41. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, et al. (2008) Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 52: 3284-3292.
42. Gubareva LV, McCullers JA, Bethell RC, Webster RG (1998) Characterization of influenza A/HongKong/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice. J Infect Dis 178: 1592-1596.
43. Larsson A, Balow RM, Lindahl TL, Forsberg PO (1993) Chicken antibodies: taking advantage of evolution-a review. Poult Sci 72: 1807-1812.
44. Kovacs-Nolan J, Phillips M, Mine Y (2005) Advances in the value of eggs and egg components for human health. J Agric Food Chem 53: 8421-8431.